Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Multiple Sclerosis

Free Subscription Articles published in Brain Retrieve available abstracts of 79 articles: HTML format

Single Articles

October 2026
1. HUNT DPJ
   Preventing autoimmunity after alemtuzumab in multiple sclerosis: regulatory T cells resist expansion.
   Brain. 2026 Oct 21:awag308. doi: 10.1093.
   PubMed    
   
   
   
2. FREEMAN SA, Liblau RS
   A novel TARGET for anti-CD20 antibody therapy in multiple sclerosis.
   Brain. 2026 Oct 17:awag360. doi: 10.1093.
   PubMed    
   
   
   
3. UHER T, Nagels G
   Mapping brain imaging heterogeneity in multiple sclerosis.
   Brain. 2026 Oct 8:awag349. doi: 10.1093.
   PubMed    
   
   
   September 2026
4. PREZIOSA P, Storelli L, Clarelli F, Pagani E, et al
   Imaging subtypes reveal distinct biological substrates and disability profiles in multiple sclerosis.
   Brain. 2026 Sep 23:awag320. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. FAROOQ R, Cutler B, Pisa M, Balaram Kuttikkatte S, et al
   Multimodal discovery of a pathogenic B cell-dependent T cell state in multiple sclerosis.
   Brain. 2026 Sep 9:awag303. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. BROWN JWL
   Untangling prognosis in multiple sclerosis.
   Brain. 2026;149:2909-2911.
   PubMed    
   
   
   August 2026
7. FOSTER MA, Wade C, Ford HL, Schmierer K, et al
   Diagnosing multiple sclerosis: implementation and unintended effects of the 2024 McDonald criteria.
   Brain. 2026 Aug 28:awag293. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. GRUT V, Ingvarsson J, Bistrom M, Jons D, et al
   Lytic Epstein-Barr virus infection and emerging autoantibodies precede multiple sclerosis prodrome.
   Brain. 2026 Aug 22:awag283. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. SORMANI MP, Wiendl H, Montalban X, Oh J, et al
   Rethinking multiple sclerosis therapy beyond clinical phenotypes.
   Brain. 2026 Aug 18:awag273. doi: 10.1093.
   PubMed    
   
   
   
10. DA SILVA MTT, Araujo AQC
    HTLV-1-associated myelopathy as a translational model of progressive neurodegeneration.
    Brain. 2026;149:2592-2603.
    PubMed     Abstract available
    
    
    July 2026
11. DARUWALLA C, Kremler C, Patti F, Ozakbas S, et al
    Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis.
    Brain. 2026 Jul 24:awag252. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. SANDGREN S, Leppert D, Kuhle J
    Propionic acid and neurofilament light chain in multiple sclerosis.
    Brain. 2026 Jul 6:awag192. doi: 10.1093.
    PubMed    
    
    
    
13. MOSER T, Hitzl W, Lerda-Casaccia T, Unterhofer M, et al
    Propionic acid in multiple sclerosis: a phase 2b, double-blind, randomized placebo-controlled trial.
    Brain. 2026;149:2286-94.
    PubMed     Abstract available
    
    
    
14. HAY CM, Mahjoub A, Vidarsson L, Soltanieh S, et al
    Retinal hyper-reflective foci link retinal and cortical pathology in paediatric multiple sclerosis.
    Brain. 2026 Jul 1:awag235. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2026
15. DUGAST E, Shah S, Vogel I, Loret A, et al
    Blood cytotoxic natural killer-like CD8 + CD94+ T cells migrate to the brain and predict multiple sclerosis severity.
    Brain. 2026 Jun 30:awag227. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. TUR C, Susin-Calle S, Otero-Romero S, Carvajal R, et al
    Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis.
    Brain. 2026 Jun 10:awag047. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2026
17. TUR C
    High-efficacy therapy and progression independent of relapse and MRI activity in multiple sclerosis.
    Brain. 2026 May 28:awag175. doi: 10.1093.
    PubMed    
    
    
    
18. GRANBERG T
    The skull-meningeal axis: a new window into multiple sclerosis progression.
    Brain. 2026 May 28:awag177. doi: 10.1093.
    PubMed    
    
    
    
19. ARNABOLDI PM, Becker J, Nath A, Coyle PK, et al
    Designing studies for post-treatment Lyme disease and other infection-associated chronic illnesses.
    Brain. 2026 May 18:awag016. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. GEORGIEVA ZG, Howlett SK, Rainbow DB, Coppard V, et al
    Low-dose IL-2 fails to expand Tregs after alemtuzumab: insight into impaired immune tolerance in multiple sclerosis.
    Brain. 2026 May 13:awag171. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2026
21. AGUZZI EA, Desai RA, Yang Z, Davies AL, et al
    A cause and protective treatment for acute and progressive disability and grey matter atrophy.
    Brain. 2026;149:1144-1152.
    PubMed     Abstract available
    
    
    March 2026
22. JACOBS BM, Vandebergh M, Maltby VE, Dobson R, et al
    Interplay between genetic and environmental risk factors in multiple sclerosis: what have we learned?
    Brain. 2026 Mar 27:awag111. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. LEAVITT VM
    Forget processing speed: cognitive changes in multiple sclerosis call for new measurement tools.
    Brain. 2026 Mar 16:awag107. doi: 10.1093.
    PubMed    
    
    
    
24. CORAZZOLLA G, Treaba CA, Mohammadian M, Brusaferri L, et al
    Evidence of skull bone translocator protein overexpression linked to multiple sclerosis progression.
    Brain. 2026 Mar 9:awag084. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2026
25. ROLLOT F, Casey R, Kerbrat A, Edan G, et al
    Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis.
    Brain. 2026 Feb 14:awag060. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. MURARO PA, De Matteis E, Scalfari A
    A tight match: comparing the effectiveness of immune reconstitution therapies for multiple sclerosis.
    Brain. 2026 Feb 3:awag044. doi: 10.1093.
    PubMed    
    
    
    January 2026
27. VILLAR LM
    The CD5-CK2-STAT3 axis in Th17 cell polarization: implications for multiple sclerosis.
    Brain. 2026;149:9-10.
    PubMed    
    
    
    December 2025
28. BRUMMER T, Fleischer V
    Beyond clinical labels: a molecular-structural framework for multiple sclerosis subtyping.
    Brain. 2025;148:4155-4157.
    PubMed    
    
    
    
29. WILLARD C, Puglisi L, Ravi D, Dmitrieva M, et al
    Combined magnetic resonance imaging and serum analysis reveals distinct multiple sclerosis types.
    Brain. 2025 Dec 2:awaf331. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2025
30. LIN TY, McCormack B, Bacchetti A, Inserra M, et al
    Combining inter-eye differences enhances detection of optic nerve involvement in multiple sclerosis.
    Brain. 2025 Nov 26:awaf450. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. SUMOWSKI JF, Levy S, Katz Sand I, Brandstadter R, et al
    Cognition in multiple sclerosis within the modern diagnostic and treatment era.
    Brain. 2025 Nov 26:awaf446. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. BIGOTTE M, Groh AMR, Afanasiev E, Wong V, et al
    Cerebrospinal fluid-driven ependymal motile cilia defects are implicated in multiple sclerosis.
    Brain. 2025 Nov 24:awaf440. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. MACESKI AM, Benkert P, Einsiedler M, Schaedelin S, et al
    GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.
    Brain. 2025 Nov 14:awaf433. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2025
34. MUKHERJEE T, McMurran CE, Holland J, Daruwalla C, et al
    Ageing and remyelination failure in people with multiple sclerosis.
    Brain. 2025 Oct 6:awaf373. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2025
35. FURLAN R, Schaedelin S, Frederiksen JL, Watanabe M, et al
    Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.
    Brain. 2025 Sep 24:awaf345. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. FEINSTEIN A, Bar-Or A, Benedict RHB, Filippi M, et al
    Is multiple sclerosis-related depression different from depression in general? The data for and against.
    Brain. 2025 Sep 9:awaf319. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2025
37. PAPE K, Hanuscheck N, Schmaul S, Kneilmann F, et al
    Role of CD5 signalling for pro-inflammatory Th17 response in multiple sclerosis.
    Brain. 2025 Aug 25:awaf268. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. RODRIGUES P, Frare JM, Ruviaro NA, Peres DS, et al
    Advanced oxidation protein products activated TRPA1 in a neuropathic multiple sclerosis model.
    Brain. 2025 Aug 17:awaf306. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. KALINCIK T, Sharmin S, Roos I, Freedman MS, et al
    Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.
    Brain. 2025 Aug 4:awaf286. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. ABDELHAK A, Cordano C, Duncan GJ, Emberley K, et al
    Markers of axonal injury in blood and tissue triggered by acute and chronic demyelination.
    Brain. 2025;148:3011-3020.
    PubMed     Abstract available
    
    
    
41. NISHIGORI R, Hamatani M, Yoshitomi H, Kimura K, et al
    CD21lo B-cell subsets are recruited to the central nervous system in acute neuromyelitis optica.
    Brain. 2025;148:2995-3010.
    PubMed     Abstract available
    
    
    June 2025
42. CUNNIFFE NG
    Extending the role of neurofilament light in multiple sclerosis beyond measuring irreversible neurodegeneration.
    Brain. 2025 Jun 9:awaf224. doi: 10.1093.
    PubMed    
    
    
    May 2025
43. GIOVANNONI G, James L, Adeniran AA, Gold J, et al
    The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis.
    Brain. 2025 May 6:awaf170. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2025
44. GIOVANNONI G
    EBV-specific T-cell responses are telling us something important about multiple sclerosis.
    Brain. 2025 Jan 27:awaf027. doi: 10.1093.
    PubMed    
    
    
    December 2024
45. CHEN JQA, McNamara NB, Engelenburg HJ, Jongejan A, et al
    Distinct transcriptional changes distinguish efficient and poor remyelination in multiple sclerosis.
    Brain. 2024 Dec 24:awae414. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. ANDRODIAS G, Lunemann JD, Maillart E, Amato MP, et al
    De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.
    Brain. 2024 Dec 21:awae409. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. COLES A
    A blood test to predict prognosis in multiple sclerosis?
    Brain. 2024;147:3969.
    PubMed    
    
    
    November 2024
48. SUN J, Guo M, Chai L, Xu S, et al
    Distinct virtual histology of grey matter atrophy in four neuroinflammatory diseases.
    Brain. 2024;147:3906-3917.
    PubMed     Abstract available
    
    
    September 2024
49. BERGNER CG, van der Meer F, Franz J, Vakrakou A, et al
    BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis.
    Brain. 2024 Sep 25:awae293. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2024
50. MONREAL E, Fernandez-Velasco JI, Alvarez-Lafuente R, Sainz de la Maza S, et al
    Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.
    Brain. 2024 Aug 5:awae260. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2024
51. FILIPPI M, Preziosa P, Barkhof F, Ciccarelli O, et al
    The ageing central nervous system in multiple sclerosis: the imaging perspective.
    Brain. 2024 Jul 24:awae251. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. HOLM RP, Wandall-Holm MF, Magyari M
    Multiple sclerosis in Denmark (1950-2023): mean age, sex distribution, incidence and prevalence.
    Brain. 2024 Jul 20:awae245. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. TAYLOR BV, Ponsonby AL, Stein M, Lucas R, et al
    Reply: Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size.
    Brain. 2024 Jul 19:awae246. doi: 10.1093.
    PubMed    
    
    
    
54. SCHNEIDER-HOHENDORF T, Wunsch C, Falk S, Raposo C, et al
    Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation.
    Brain. 2024 Jul 18:awae244. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. CORSTEN CEA, Wokke BHA, Smolders J
    Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size.
    Brain. 2024 Jul 16:awae238. doi: 10.1093.
    PubMed    
    
    
    April 2024
56. HUANG J, Tengvall K, Bomfim Lima I, Hedstrom AK, et al
    Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis.
    Brain. 2024 Apr 17:awae110. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2024
57. MAINERO C, Miscioscia A, Treaba CA
    Cortical remyelination in multiple sclerosis: a target for disease monitoring and intervention.
    Brain. 2024 Mar 27:awae083. doi: 10.1093.
    PubMed    
    
    
    January 2024
58. HERRANZ E, Treaba CA, Barletta VT, Mehndiratta A, et al
    Characterization of cortico-meningeal translocator protein expression in multiple sclerosis.
    Brain. 2024 Jan 30:awae030. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. LAZZAROTTO A, Hamzaoui M, Tonietto M, Dubessy AL, et al
    Time is myelin: early cortical myelin repair prevents atrophy and clinical progression in multiple sclerosis.
    Brain. 2024 Jan 24:awae024. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. BAGNATO F, Sati P, Hemond CC, Elliott C, et al
    Imaging chronic active lesions in multiple sclerosis: a consensus statement.
    Brain. 2024 Jan 16:awae013. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. SCHWAB N
    Transcriptomics reveals CSF cellular composition in multiple sclerosis but detects no viral RNA.
    Brain. 2024 Jan 5:awae006. doi: 10.1093.
    PubMed    
    
    
    
62. JAMANN H, Desu HL, Cui QL, Halaweh A, et al
    ALCAM on human oligodendrocytes mediates CD4 T cell adhesion.
    Brain. 2024;147:147-162.
    PubMed     Abstract available
    
    
    December 2023
63. MARZIALI LN, Hwang Y, Palmisano M, Cuenda A, et al
    p38gamma MAPK delays myelination and remyelination and is abundant in multiple sclerosis lesions.
    Brain. 2023 Dec 21:awad421. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. CALLEGARI I, Oechtering J, Schneider M, Perriot S, et al
    Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5.
    Brain. 2023 Dec 20:awad424. doi: 10.1093.
    PubMed     Abstract available
    
    
    
65. CREE BAC
    Herpes viral infection and the multiple sclerosis prodrome: is HHV-6A infection a second hit?
    Brain. 2023 Dec 18:awad418. doi: 10.1093.
    PubMed    
    
    
    
66. BUTZKUEVEN H, Ponsonby AL, Stein MS, Lucas RM, et al
    Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome.
    Brain. 2023 Dec 12:awad409. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. BAN M, Bredikhin D, Huang Y, Bonder MJ, et al
    Expression profiling of cerebrospinal fluid identifies dysregulated antiviral mechanisms in multiple sclerosis.
    Brain. 2023 Dec 1:awad404. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2023
68. KEDDIE S, Smyth D, Keh RYS, Chou MKL, et al
    Peripherin is a biomarker of axonal damage in peripheral nervous system disease.
    Brain. 2023;146:4562-4573.
    PubMed     Abstract available
    
    
    October 2023
69. GRUT V, Bistrom M, Salzer J, Stridh P, et al
    Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis.
    Brain. 2023 Oct 31:awad374. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. BERNARD HEALEY SA, Giovannoni G, Noyce A, Dobson R, et al
    Impact of multiple sclerosis risk alleles on the plasma proteome.
    Brain. 2023 Oct 18:awad363. doi: 10.1093.
    PubMed    
    
    
    September 2023
71. MATSUMOTO Y, Kaneko K, Takahashi T, Takai Y, et al
    Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
    Brain. 2023;146:3938-3948.
    PubMed     Abstract available
    
    
    August 2023
72. FLEISCHER V, Gonzalez-Escamilla G, Pareto D, Rovira A, et al
    Prognostic value of single-subject grey matter networks in early multiple sclerosis.
    Brain. 2023 Aug 29:awad288. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. LEBRUN-FRENAY C, Okuda DT, Siva A, Landes-Chateau C, et al
    The radiologically isolated syndrome: revised diagnostic criteria.
    Brain. 2023;146:3431-3443.
    PubMed     Abstract available
    
    
    June 2023
74. SHARMIN S, Roos I, Simpson-Yap S, Malpas C, et al
    The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
    Brain. 2023 Jun 27:awad218. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. HENRIET E, Martin EM, Jubin P, Langui D, et al
    Monitoring recovery after CNS demyelination, a novel tool to de-risk pro-remyelinating strategies.
    Brain. 2023;146:2453-2463.
    PubMed     Abstract available
    
    
    
76. CORTESE R, Battaglini M, Prados F, Bianchi A, et al
    Clinical and MRI measures to identify non-acute MOG-antibody disease in adults.
    Brain. 2023;146:2489-2501.
    PubMed     Abstract available
    
    
    April 2023
77. CHARABATI M, Zandee S, Fournier AP, Tastet O, et al
    MCAM+ brain endothelial cells contribute to neuroinflammation by recruiting pathogenic CD4+ T lymphocytes.
    Brain. 2023;146:1483-1495.
    PubMed     Abstract available
    
    
    
78. GUO Y, Lennon VA
    A distinctive IgG-mediated pathogenesis for primary progressive multiple sclerosis?
    Brain. 2023 Apr 3:awad107. doi: 10.1093.
    PubMed    
    
    
    March 2023
79. LIN J, Zhou J, Xu Y
    Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis.
    Brain. 2023 Mar 2:awad070. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum